Setting a new standard for fast and consistent absorption from swallow tablets
Imaginot Pty Ltd is a privately owned company established in 1999, based in Brisbane, SE Queensland. It was a spin out from an Australian pharmaceutical company, Herron Pharmaceuticals which was a market leader in paracetamol and ibuprofen products.
While the initial focus was to improve the speed of absorption of paracetamol from swallow tablets, the Imaginot R&D program led to the development of the platform Surge Dose® technology that has wider application to many other drugs that are taken orally.
Surge Dose® significantly improves absorption by reducing the dose to dose variability that results from variable in vivo disintegration and dissolution and gastric emptying, with faster time to peak plasma concentrations.
This formulation approach is applicable to NMEs as well as marketed drugs where it offers the opportunity for lifecycle management or 505(b)(2) programs.
Imaginot has worked in partnership with several multinational pharmaceutical companies to improve the absorption of a number of different drugs. The Surge Dose® technology has been licensed for several drugs, with one product already marketed and others in various stages of development and registration.
Imaginot has patents covering the application of its Surge Dose® technology to paracetamol and paracetamol combinations, basic and amphoteric drugs, and acidic and unionised drugs filed in Australia, USA, Canada, India and Europe.